1. Home
  2. DGLY vs DRMA Comparison

DGLY vs DRMA Comparison

Compare DGLY & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digital Ally Inc.

DGLY

Digital Ally Inc.

HOLD

Current Price

$1.07

Market Cap

2.5M

Sector

Technology

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$2.49

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGLY
DRMA
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
2.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
DGLY
DRMA
Price
$1.07
$2.49
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
806.1K
104.0K
Earning Date
12-29-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,097,965.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.08
$2.34
52 Week High
$1,600.00
$23.70

Technical Indicators

Market Signals
Indicator
DGLY
DRMA
Relative Strength Index (RSI) 35.36 35.84
Support Level $1.27 $2.66
Resistance Level $1.41 $2.98
Average True Range (ATR) 0.13 0.27
MACD -0.00 0.01
Stochastic Oscillator 0.00 18.21

Price Performance

Historical Comparison
DGLY
DRMA

About DGLY Digital Ally Inc.

Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Share on Social Networks: